Ahead of Berkshire’s next moves, a fresh look at Buffett’s three “favorite stocks” points to very different risk pictures

A market article circulating on Yahoo Finance is prompting fresh discussion around Warren Buffett’s best-known stock preferences by spotlighting three “favorite stocks” and asking whether investors should treat each as a buy, sell or hold based on prevailing market prices.

The piece, published July 15, centers on Apple, American Express and Coca-Cola and sets up a three-part comparison. The underlying theme is that even when a company fits the broad Buffett style of quality and staying power, the stock’s current valuation can change the near-term decision calculus.

In the article’s framing, Berkshire Hathaway’s approach is presented as “patient money” that can be reshuffled over time, implying that what looks like a steady long-term commitment may still involve periodic positioning changes depending on price, expected returns and competing opportunities.

However, the post does not provide new, company-specific disclosures about Berkshire Hathaway’s recent trading. Instead, it uses the three familiar names and current market prices as the lens for debate, meaning the analysis is driven more by valuation and momentum than by any announced Berkshire transactions.

For investors trying to interpret what such lists may announcement, the key takeaway is methodological rather than factual: valuation alone can make the same business look attractive or expensive at different times. Apple, American Express and Coca-Cola represent distinct business models, which tends to matter when markets re-rate industries, earnings durability and interest-rate expectations.

Still, because the article is an external market write-up rather than an investor-relations filing, it leaves unanswered what, if anything, Berkshire actually added or trimmed around the time of publication. The company’s actual portfolio changes, if any, would normally be reflected in later regulatory disclosures rather than a valuation commentary.

Berkshire Hathaway itself, through its reporting, can change the story quickly. Without seeing a recent filing that enumerates purchases, sales, or cost basis changes for these holdings, it would be premature to translate the “buy, sell or hold” framing into a claim about Berkshire’s exact current actions.

What to watch next is whether Berkshire Hathaway’s subsequent disclosures clarify the status of these three positions, including whether holdings increased, decreased, or remained steady, and how much of the “patient money” argument is based on valuation versus on management’s longer-term outlook for each business.